Key Features of CCR8 Validated MAbs • Panel of MAbs, nanomolar and subnanomolar EC 50 • 99% human antibodies (excluding CDR regions) • Reactivity with orthologs facilitating …

• Chemokine receptor 8 (CCR8) is a G protein-coupled receptor (GPCR) that is highly upregulated by intratumoral Tregs compared to their peripheral counterparts and other immune cell types

• CCR8 is a G protein-coupled chemokine receptor (GPCR) that is predominantly upregulated on tumor-resident Tregs. Preferential depletion of Tregs in the TME may be achieved through …

Decreasing regulatory T cells (Tregs) and increasing effector T cells (Teffs) in tumors may prevent the development of immunotherapy resistance. LM-108 is a novel humanized anti-CCR8 …

ccr8 RenMab TM mice Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses

We have hypothesized that a strong anti-CCR8 arm may provide preferential inhibition of CTLA-4 on CCR8+CTLA-4+ intra-tumor Tregs and have synergistic effects on Tregs in TME. …

CHS-114 an afucosylated mAb that binds CCR8, depletes itTregs, and enhances toripalimab- (tori; anti-PD-1 mAb) mediated T cell activation. Here, we present preliminary results of the …

2024年4月8日 · Three fully human monoclonal antibodies targeting CCR8 were developed and characterized in CCR8 knock-out RenMabTM mice. These antibodies recognize a unique …

A therapeutic antibody that binds CCR8 could find and kill tumor-associated Tregs, opening the door to cancer-fighting cells and other therapies. MAbs targeting CCR8 could be used either …

CHS-114: a Cytolytic Anti-CCR8 Antibody that Depletes Tumor-Infiltrating Regulatory T Cells as a Treatment for Head and Neck Squamous Cell Carcinoma